← back to search

Bettina Müller

University of Chile · CL
Area of research
Genetics · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, Estrogen and related hormone effects, Advanced Breast Cancer Therapies, and BRCA gene mutations in cancer.
h-index
25
citations
5,051
works
174
NIH funding
primary concept
Medicine
email

Recent publications

Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer
JAMA Oncology 2024cited by 10position: middledoi
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Annals of Oncology 2023cited by 44position: middledoi
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Journal of Clinical Oncology 2022cited by 56position: middledoi
Gallstones, Body Mass Index, C-Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data
STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) 2021cited by 0position: middle
Gallstones, Body Mass Index, C‐Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data
Hepatology 2020cited by 102position: middledoi
Epigenome‐Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer
Hepatology 2020cited by 52position: middledoi
ABCB1/4 gallbladder cancer risk variants identified in India also show strong effects in Chileans
Cancer Epidemiology 2020cited by 17position: middledoi
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
The Lancet 2018cited by 1,311position: middledoi
ADAR1-mediated RNA-editing of 3′UTRs in breast cancer
Biological Research 2018cited by 63position: middledoi
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology 2017cited by 121position: middledoi
Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile
PLoS Genetics 2017cited by 65position: middledoi
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
The Lancet 2012cited by 2,030position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Katherine Marcelain · Heidelberg University3 papers (2017–2020)Felix Boekstegers · Heidelberg University2 papers (2017–2020)Carol Barahona Ponce · Zimmer Biomet (Netherlands)2 papers (2017–2020)Justo Lorenzo Bermejo · University Hospital Heidelberg2 papers (2017–2020)Benjamin Goeppert · Kantonsspital Baselland1 papers (2020–2020)Ricardo A. Verdugo · University of Chile1 papers (2018–2018)Dominique Scherer · Heidelberg University1 papers (2020–2020)Olivier Harismendy · Acadia Pharmaceuticals (United States)1 papers (2018–2018)Paola Pérez · National Institutes of Health1 papers (2018–2018)María Cátira Bortolini · Universidade Federal do Rio Grande do Sul1 papers (2017–2017)Macarena Fuentes‐Guajardo · University of Tarapacá1 papers (2017–2017)Fernando Gabler · Hospital San Borja Arriarán1 papers (2020–2020)Gonzalo de Toro · Austral University of Chile1 papers (2020–2020)Trine B. Rounge · Oslo University Hospital1 papers (2020–2020)Iván Gallegos · Production Development Corporation1 papers (2020–2020) · 1 papers (2018–2018)Alicia Colombo · Fluid Operations (Germany)1 papers (2020–2020)Rosa González Silos · University Hospital Heidelberg1 papers (2017–2017)Erik Morales · Hospital Regional de Talca1 papers (2020–2020)Carla Gallo · Universidad Peruana Cayetano Heredia1 papers (2017–2017)